Targeting the cGAS-STING Pathway Using a Homogenous, HTS Compatible Transcreener cGAS Assay
Discover cGAS Inhibitors with the Transcreener cGAMP cGAS Assay
The Transcreener cGAMP cGAS Assay directly measures cyclic GMP-AMP (cGAMP) produced by cyclic GMP-AMP synthase (cGAS, C6orf150, 2'3'-cGAMP Synthase). By measuring the production of cGAMP researchers can effectively determine the activity of the cGAS enzyme. The assay provides a powerful tool to screen entire compound libraries for cGAS modulators to help find new therapeutics targeting the cGAS-STING pathway.
cGAS is an Important Messenger in the STING Pathway
The presence of DNA in the cytosol of eukaryotic cells is an indicator of infection or cellular damage, and it elicits a robust immune response, driven by type I interferon (IFN) induction. cGAS is an exquisitely sensitive sensor for double-stranded DNA in the cytoplasm. Binding of DNA activates the enzyme to produce a unique cyclic dinucleotide second messenger, cGAMP, which acts as an agonist for the STING (stimulator of interferon genes) receptor, leading to induction of a type I interferon response.

Direct Detection of cGAMP to Measure cGAS Enzymatic Activity


Recent Posts
NIH Awards BellBrook Labs Phase II Grant to Develop Drugs Targeting the cGAS-STING Pathway for Lupus and Related Autoimmune Diseases
New TR-FRET Readout Now Available with the Transcreener cGAMP cGAS Assay
Previously Recorded Webinar – Streamline cGAS Inhibitor Discovery with the Transcreener® cGAS Assay
BellBrook Labs Launches Transcreener cGAS Activity Assay to Accelerate Drug Discovery
BellBrook Labs Receives NIH Grant for the Discovery of cGAS Inhibitors to Treat Autoimmune Diseases